10-K: STAAR Surgical Reports Significant Losses Amid China Slowdown

STAAR Surgical reported a substantial net loss and revenue decline in fiscal 2025, primarily driven by macroeconomic challenges and weak consumer demand in China, alongside costs from a terminated merger and leadership changes.

Summary

• Net sales for fiscal year 2025 decreased by 23.7% to $239.4 million, down from $313.9 million in fiscal 2024.
• The company incurred a net loss of $80.4 million in fiscal 2025, a significant increase from the $20.2 million net loss in fiscal 2024.
• Sales in the Asia Pacific (APAC) region, heavily influenced by China, decreased by 32% with ICL units down 35%.
• China distributors accounted for approximately 32% of consolidated net sales in fiscal 2025, a sharp decline from 51.7% in 2024 and 57.2% in 2023.
• The proposed merger with Alcon Research, LLC was terminated on January 6, 2026, after stockholders voted against it, resulting in $17.1 million in related professional fees and expenses in fiscal 2025.
• Restructuring, impairment, and related charges totaled $28.6 million in fiscal 2025, stemming from leadership realignment, workforce reduction, and asset impairments.
• The company expanded its ICL manufacturing capabilities in Nidau, Switzerland, to supplement U.S. capacity and mitigate tariff risks.
• STAAR Surgical achieved a milestone of selling over 4,000,000 ICLs worldwide by February 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a negative sentiment due to the significant decline in net sales, substantial net loss, and ongoing macroeconomic headwinds in the crucial China market, despite strategic realignments and product milestones.

Positives

• The company achieved a significant milestone, having sold an aggregate of more than 4,000,000 ICLs worldwide by February 2026.
• Sales in the Europe, Middle East, and Africa (EMEA) region increased by 3% with ICL unit growth of 10% in fiscal 2025.
• Sales in the Americas region increased by 14% with ICL unit growth of 10% in fiscal 2025, primarily driven by U.S. growth.
• Expansion of ICL manufacturing capabilities in Nidau, Switzerland, provides optionality and reduces tariff risk.
• The EVO ICL is the only foldable, minimally invasive posterior chamber phakic intraocular lens approved for sale in the U.S. and is believed to be the world's largest selling phakic IOL.

Negatives

• Net sales decreased by 23.7% in fiscal 2025 compared to 2024, and by 2.6% in 2024 compared to 2023.
• The company reported a net loss of $80.4 million in fiscal 2025, following a $20.2 million net loss in fiscal 2024, breaking a decade-long trend of annual net sales growth and profitability since 2018.
• The sluggish economy and weak consumer consumption in China significantly impacted financial results in fiscal 2024 and 2025, and are expected to continue impacting demand in fiscal 2026.
• Merger transaction and related costs of $17.1 million were incurred in fiscal 2025 due to the terminated Alcon merger.
• Restructuring, impairment, and related charges of $28.6 million were recognized in fiscal 2025, including severance, consulting, and asset impairment expenses.
• Gross profit margin decreased to 76.2% in 2025 from 76.3% in 2024 and 78.4% in 2023, due to higher manufacturing costs per unit from lower production volume and increased inventory reserves.
• Global employee turnover rate in fiscal 2025 was approximately 32.2%, higher than the medical device industry average of 19.7%.
• The company's defined benefit pension plans are underfunded by approximately $6.4 million as of January 2, 2026.

Risks

• Continued reliance on independent distributors in international markets, particularly China, exposes the company to commercial and compliance risks, including potential sales reductions if distributors underperform or cease operations.
• A significant or prolonged slowdown in the Chinese economy or worsening trade relations between the U.S. and China could materially impact business and results of operations, as China accounted for 32% of fiscal 2025 consolidated net sales.
• Unfavorable economic conditions or negative publicity concerning complications of laser eye surgery or medical devices in general could hurt sales of refractive products, which are elective procedures not typically covered by health insurance.
• Disruptions in the supply chain or failure to adequately forecast product demand could result in significant delays or lost sales, especially given reliance on single-sourced raw materials and proprietary collagen-containing materials.
• Foreign currency fluctuations, particularly involving the Japanese yen, euro, and Swiss franc, could result in volatility of revenue and profitability, as 91% of total sales in 2025 were outside the U.S.
• Vulnerability to any loss of use of the principal manufacturing facility in Monrovia, California, due to natural disasters or operational failures, could have a material adverse effect.
• Public health crises, political crises, and other catastrophic events outside of control may impact business and operating results globally.
• The loss of key employees or inability to recruit, hire, and retain skilled personnel could negatively impact the ability to effectively manage and expand the business.
• Intense competition from much larger companies (e.g., Alcon, J&J, Bausch Health, Carl Zeiss Meditec AG) in laser vision correction and low-cost Asian manufacturers in phakic implants.
• Potential losses due to product liability claims that may exceed insurance coverage or divert resources.
• Exposure to environmental liability due to the use of hazardous materials and an irradiator in manufacturing and R&D activities.
• Data corruption, cyber-based attacks, or network security breaches and/or noncompliance with data protection and privacy regulations could negatively impact operations and reputation.
• Acquisitions of technologies, products, and businesses could disrupt operations, involve increased expenses, and present unforeseen risks.
• Inability to successfully manage growth, including challenges with manufacturing output, inventory levels, and implementation of new ERP systems, could adversely affect business.
• Corporate responsibility, specifically related to environmental, social, and governance (ESG) matters, may impose additional costs, expose the company to reputational and emerging risks, and could negatively affect the business.
• Failure to keep pace with advances in the industry and persuade physicians to adopt new products could lead to declining sales.
• Extensive government regulation worldwide, including complex and costly premarket clearance/approval processes, increases costs and could prevent product sales.
• Non-compliance with anti-corruption laws (e.g., U.S. FCPA) could lead to penalties or harm reputation, especially in markets where doctors and hospital administrators are deemed government officials.
• Product recalls, whether voluntary or mandatory, could result in lost sales, damage to reputation, and significant costs for corrective actions or replacement products.
• Changes in U.S. FDA or international regulations related to product approval, including retroactive changes, could make the company less competitive.
• If products cause or contribute to a death or serious injury, the company may face voluntary corrective actions, agency enforcement actions, and harm to results.
• Modifications to products may require new marketing clearances or approvals, potentially leading to marketing cessation or product recalls.

Future Outlook

The company aims to return to sustainable, profitable growth by focusing on three strategic imperatives for 2026: focused growth in key markets, prioritizing investments that support long-term value creation (including surgeon education and enhanced systems), and accelerating innovation with a full launch of EVO+ in China and additional lens sizes. Management expects the sluggish economy and weak consumer consumption in China to continue impacting demand for ICLs in fiscal 2026.

Management Comments

• "We believe our EVO lenses are an Evolution in Visual Freedom designed to provide premium refractive outcomes while optimizing patient comfort."
• "Our goal is to position our refractive lenses throughout the world as primary and premium solutions for patients seeking visual freedom from wearing eyeglasses or contact lenses while achieving excellent visual acuity through refractive vision correction."
• "The Company is navigating market headwinds, geopolitical factors and a dynamic environment in key regions, including China."
• "We believe we have a significant opportunity to fundamentally transform how myopia and other refractive conditions are treated."
• "We want to be the first choice for doctors and for patients seeking visual freedom from wearing eyeglasses or contact lenses."
• "We believe growth must be sustainable."
• "Innovation remains central to the Company's future."

Industry Context

StockSavvy.ai notes that STAAR Surgical operates in the highly competitive ophthalmic surgical product market, primarily competing against laser vision correction procedures (LASIK, SMILE) offered by major players like Alcon, Johnson & Johnson, Bausch Health Companies, and Carl Zeiss Meditec AG. The company also faces competition from other phakic implantable lenses, including emerging low-cost versions from Asian manufacturers. Despite these competitive pressures, the growing global incidence of myopia and a perceived reduction in patient interest in LASIK due to negative publicity present a significant market opportunity for STAAR's ICLs, positioning them as a safe and effective alternative.

Comparison to Industry Standards

• STAAR Surgical's EVO ICL is uniquely positioned as the only foldable, minimally invasive posterior chamber phakic intraocular lens approved for sale in the U.S., and is considered the world's largest selling phakic IOL.
• The proprietary Collamer lens material offers compelling clinical advantages over competing lenses made from silicone or acrylic, contributing to a strong track record of safety, effectiveness, and high patient satisfaction.
• Competitors in laser vision correction include industry giants like Alcon, Johnson & Johnson, Bausch Health Companies, and Carl Zeiss Meditec AG, which possess significantly greater financial, technical, marketing, and distribution resources.
• Other phakic implantable lens competitors include Biotech Vision Care, Care Group, Eyebright, and Ophtec, with emerging low-cost Asian manufacturers increasing market competition.

Management Changes

Corporate Governance

Legal Proceedings

• The company is involved in various legal proceedings and other matters arising in the normal course of business, including contractual rights and obligations, employment matters, or product liability claims.
• In 2022, a Japanese trade association ruled that the company's subsidiary in Japan improperly implemented a program with surgeons and hospitals to obtain videos of cataract surgeries where its cataract intraocular lenses were used.

Related Party Transactions

• Advances to certain non-executive employees amounted to $301,000 as of January 2, 2026, compared to $3,000 as of December 27, 2024.

Stakeholder Impact

• **Shareholders:** Experienced significant stock price volatility, no cash dividends paid, and a concentration of ownership among a few investors (Broadwood Partners owns ~31%), which can influence corporate decisions and stock price.
• **Employees:** High global turnover rate (32.2% in fiscal 2025) indicates potential instability and challenges in talent retention, exacerbated by leadership realignment and workforce reductions.
• **Customers:** Potential for supply disruptions due to reliance on single-sourced raw materials and manufacturing facilities, and impact from macroeconomic conditions in key markets like China affecting demand and purchasing patterns.
• **Creditors:** Underfunded defined benefit pension plans ($6.4 million) represent a future obligation that may require significant cash payments, potentially impacting liquidity.
• **Suppliers:** Disruptions in the supply chain, particularly for single-sourced components, could affect production and lead to lost sales.

Next Steps

• Full launch of EVO+ in China to expand product offering.
• Launch of additional lens sizes to allow for greater surgeon flexibility.
• Continue to prioritize investments that support long-term value creation, with a clear focus on what drives results and expands profits.
• Further educate and train ophthalmic surgeons about ICLs and the ICL procedure.
• Leverage the EVO Experience Center for comprehensive, hands-on training and education.
• Invest in enhanced systems and tools to make ordering and fulfillment faster and easier.
• Drive awareness of the ICL procedure to reach more potential patients and communicate clinical benefits.
• Adjust production output based on forecasted demand and optimize inventory levels in fiscal 2026.
• Search for a permanent Chief Executive Officer.

Key Dates

Recommendation

STAAR Surgical is navigating a challenging period marked by significant financial underperformance, a substantial net loss, and a sharp decline in sales from its key China market. While the company has taken decisive steps in leadership realignment and strategic focus, including manufacturing expansion and innovation, the immediate outlook remains uncertain due to ongoing macroeconomic headwinds and the costs associated with restructuring. The termination of the Alcon merger and the influence of activist shareholders introduce further complexity. Given the strong competitive advantages of its ICL technology and long-term market opportunities in myopia correction, a 'hold' recommendation is appropriate. Investors should monitor the effectiveness of the new leadership, the recovery of the China market, and the impact of strategic initiatives on sales growth and profitability before considering further investment.

Keywords

Implantable Collamer Lenses, ICL, Ophthalmic Surgery, Refractive Surgery, Myopia Correction, EVO ICL, Phakic IOL, Medical Devices, China Market, SEC Filing, 10-K, Vision Correction, Collamer, FDA Approval, Corporate Governance